• The Barrow Neuroplex
  • Find a Doctor
  • International Patients
  • Contact Us
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • News & Stories
  • Transfer a Patient

    Enrollment Information

    Call (602) 406-4771 or E-Mail [email protected]

    This is a multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of 1200 mg arimoclomol (400 mg TID) over a 76-week treatment period with patients who have Amyotrophic Lateral Sclerosis (ALS) and, more specifically look to find if arimoclomol extends your ability to breathe on your own, improves survival, functional health and safety as assessed with CAFS (Combined Assessment of Function and Survival). The study visits consists of both in-person and remote visits (telephone calls).

    Principal Investigator: Shafeeq Ladha, MD

    Enrollment Contact
    Norvie Alibillar
    (602) 406-4771
    [email protected]

    About Barrow Neurological Institute
    Since our doors opened as a regional specialty center in 1962, we have grown into one of the premier destinations in the world for neurology and neurosurgery. Our experienced, highly skilled, and comprehensive team of neurological specialists can provide you with a complete spectrum of care–from diagnosis through outpatient neurorehabilitation–under one roof. Barrow Neurological Institute: Discover. Educate. Heal.